Deoxycholic acid (DCA), a secondary bile acid (BA), and ursodeoxycholic acid (UDCA), a tertiary BA, cause opposing effects in vivo and in cell suspensions. Fluorescent analogues of DCA and UDCA could help investigate important questions about their cellular interactions and distribution.
Introduction
The secondary bile acid (BA), deoxycholic acid (DCA, 1 Figure 1 ) is a putative promoter of intestinal carcinogenesis. DCA causes DNA fragmentation, oxidative stress, Golgi fragmentation and apoptosis 1 . Conversely, the clinically used ursodeoxycholic acid (UDCA, 2 Figure 1 ) is cytoprotective, immunomodulatory, anti-inflammatory and anti-apoptotic. 2 In general, UDCA's effects oppose those of DCA. [3] [4] [5] For example, pre-treatment with UDCA can prevent DCA induced apoptosis and Golgi fragmentation in colon cancer cells. 6 The divergent cellular effects of DCA and UDCA have been widely investigated and there has been progress in characterising some of the molecular mechanisms involved [7] [8] [9] [10] .
However, new tools and strategies are required to investigate direct cellular interactions of the compounds, their uptake and distribution. Fluorescent steroid analogues can prove useful for this kind of problem. Such compounds may also be used to probe interacting proteins and related cellular transport mechanisms.
The 4-nitrobenzo-2-oxa-1,3-diazole (NBD) group is a particularly useful reporter group in this context because of its relatively low steric impact, its sensitivity to its environment, satisfactory quantum yield and stability. 11, 12 In the BA field, the synthesis and chemical characterisation of 3-,7-and 12-α-and β NBD analogues of cholic acid (CA, Figure  1a ) and their tauro conjugates have been reported, followed by comprehensive studies of their uptake and hepatic metabolism in vitro and in rats. [12] [13] [14] Recently, the 3-and 7-aminoNBD analogues of CA were studied as uptake probes for flow cytometry in isolated rat hepatocytes. 15 NBDlabelled 24-lysyl conjugates of UDCA ( Figure 1a ) and DCA have been studied as substrates for hepatic 16 and intestinal transport proteins. 17 Other investigations into (tauro)-UDCA have employed the UDCA 7-NBD analogue. 5, 18, 19 Astonishingly, the 3-deoxy 3-NBD-amino derivatives of DCA and UDCA have not been reported to date. Placement of the fluorescent reporter group at C-3 appears to us to be 4 optimal for exploring the disposition of UDCA and DCA because this preserves the 7-and 12-OH groups that account for the differing chemical and biological properties of the parent compounds. Importantly, C-3 modification also preserves the characteristic free bile acid side chain. Structural studies probing the interaction of UDCA with cognate proteins would also support incorporation of a reporter group at the BA C3. In the 3.0 Å crystal structure of human type III 3α-hydroxysteroid dehydrogenase (HSD)/bile acid binding protein (AKR1C2) complexed with NADP(+) and UDCA anion, the carboxylate group of UDCA was modelled in the oxyanion hole, deep in the protein with the 3-OH solvent exposed (11513593, PDB 1 ihi). The liver cytosolic bile acid binding protein (BABP) binds BAs in a similar fashion, which led to the elegant design of diagnostic compounds elaborated at C-3 with gadolinium binding EDTA groups. 20 Additionally, various SAR surveys and QSAR models of the human apical sodium-dependent bile acid transporter (ASBT, SLC10A2) suggest that the C3-OH is tolerant of modification. 21, 22 Finally, various bile acid carrier pro-drug conjugates have proven that intestinal bile acid transporters can tolerate payload incorporation at C-3.
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We have synthesised isomeric 3-deoxy 3-NBD-amino derivatives of UDCA and DCA ( Figure 1b ) as probes for studying the distribution of these important steroids. A control compound lacking the steroidal nucleus (7) was also prepared to detect non-specific effects.
In order to assess the suitability of the new analogues for investigating the disposition of the parent BAs, we have studied their uptake into polarised monolayers of intestinal epithelial
Caco-2 cells. The Caco-2 cell line exhibits many of the features of the normal intestinal epithelium including expression of various BA transporter proteins, such as the sodiumdependent bile acid transporter (ASBT) and various members of the organic aniontransporting peptide (OATP) subfamily. 24, 25 Caco-2 cells are therefore routinely used for assessing bile acid uptake and transport 26 and they are considered a suitable model for preliminary assessment of the NBD analogues as surrogates of DCA and UDCA. 5 The uptake of the DCA and UDCA 3-NBD compounds 3 and 5 was strikingly structure and stereo-specific. The DCA -analogue was sufficiently rapidly taken up to suggest general applicability in the detection of active transport processes with significant practical advantages over experimental set-ups utilising radiolabelled substrates. 6 
Results/Discussion

Chemistry
The NBD compounds (3) (4) (5) (6) were produced as shown in Scheme 1 by formation of the appropriate azides, reduction and displacement of NBD chloride. The orthogonally protected formate-methyl esters of UDCA and DCA (8, 9) were obtained in three steps from the parent bile acids. In order to produce the β-NBD compounds, these were first converted to the corresponding 3-α mesylates (10 and 11), followed by SN2 substitution to give the β-azides.
In early experiments the 3-amino-NBD group was found to be labile to conditions required to remove the formyl protection. Therefore, the formate esters were selectively removed (acetyl chloride in dry MeOH) at the azide stage to yield 12, 13. The α-azides were reduced and BOC-protected in situ followed by purification by flash chromatography. The BOC protection was removed, the NBD introduced and finally the 24-ester groups hydrolysed to give 4 and 6.
The α-compounds 3, 5 required amine introduction at C-3 with retention of configuration.
After several unsuccessful attempts with introduction of methanesulfonate, we turned to bromide and generated 3-βbromides 14, 15 using a mixture of P(Ph 3 ) 3 and Nbromosuccinimide in THF at low temperature. Azide displacement of the β-bromides producing 16, 17 was faster than the displacement of the α-mesylates in the 3-β series (10, 11) . The route to the α-NBD compounds was otherwise similar to that used to generate the β-compounds with regioselective deformylation, reduction, BOC protection and purification, de-BOC, NBD formation and de-esterification. Amino analogues of cholic acid and their NBD derivatives have been produced by stereoselective reduction of the corresponding oximes. The current approach is longer but it is clean, high yielding and the SN2 substitution provides stereochemical control. The NBD derivative of cyclohexylamine was obtained by 7 direct treatment of the amine with NBD chloride. The NBD compounds were bright orange crystalline solids, pure by HPLC (>98%) and their structure confirmed by HRMS/NMR.
Stability and physicochemical characterisation
The stability of 3NBD UDCA was assessed in pH 7.4 buffer (37°C) using HPLC to monitor remaining compound as a function of time. There was no change in the LCfluorescence peak area over 24 h under these conditions showing that the 3-NBD group was stable. The same HPLC method could also be used to assess lipophilicity. The β-compounds (calculated capacity factor (k`) for 3β-NBD-DCA was 7.3 and for 3β-NBD-UDCA 5.1) were more polar than the corresponding α-compounds (k` for 3α-NBD-DCA was 10.8 and for 3α-NBD-UDCA 5.6). As expected the DCA analogues were more hydrophobic than the corresponding UDCA analogues.
Photo/physical characterization
The UV/Vis absorption spectra of 3-6 measured in ethanol solution exhibited maxima at 228, 335 and 470 nm (Table 1) . The -compounds were red-shifted relative to the -compounds by around 5 nm (Figure 2 ). The fluorescence emission spectra for 3-6 exhibited maxima at  Em 537 nm with a 2-3 nm blue shift for the α-isomers ( Em was recorded using an  abs of 470 nm). These values were not affected by oxygen exposure. They are broadly in agreement with previously reported fluorescence values for cholic acid NBD derivatives.
13, 15
Cell viability
Bile acids can cause apoptosis through intrinsic and extrinsic pathways and necrosis through detergent effects. 8 The effect of derivatising the bile acids is not predictable though toxicity may be related to physicochemical properties such as hydrophobicity. 10 Since the NBD-bile acids were designed to investigate the disposition and uptake of the parent compounds, it was important to characterise their effect on cell viability. The cell viability effects of isomeric NBD-BAs (1-100 μM) was therefore measured using the MTT assay after incubating Caco-2 8 monolayers with the compounds for up to 100 min. The cytoxicity of the compounds was also assessed in other relevant cells lines including oesophageal adenocarcinoma (SKGT-4) and hepatic cancer cell lines (HUH-7). Compounds 3-6 did not affect cell viability in any of these cell lines up to 24 h up to 100 μM.
Caco-2 uptake
The time-course of uptake of 3-6 (10 µM) into Caco-2 cell monolayers was studied at 37°C
(which included contributions from active and passive uptake) and at 4°C (which reflects only passive diffusion) ( Figure 2 ). In general, uptake increased in a time-dependent manner for up to 60 min. Differences in uptake of the β compounds (4 and 6) between 37°C and 4°C
were not significant (P = 0.12 and P = 0.25 for 4 and 6, respectively) ( Figure 2B and D). The β compounds were therefore taken up exclusively through passive diffusion at 37°C. In contrast, uptake of the α-compounds 3 and 5 at 37°C was significantly higher (P < 0.01) to that at 4°C ( The Caco-2 cell line has been used to assess the permeability of various bile acid pro-drug conjugates and it exhibits active uptake of sterically bulky 24-side chain peptide conjugates. 27 The high diastereoselectivity of the process as well as the Eadie-Hofstee transformation suggest that the active transport process was mediated by a single transporter site. The use of aminoNBD bile acids as fluorescent tools goes back almost 20 years to the synthesis, characterisation, distribution and metabolism of 3-, 7-and 12-aminoNBD analogues of CA. [12] [13] [14] In an interesting re-exploration of some of these compounds, Rohacova et al. reported that 3α3β, 7α and 7β NBD CA accumulate in freshly isolated rat hepatocytes in a manner that was transporter mediated, because uptake was markedly attenuated by troglitazone, an inhibitor of hepatic NCTP and OATP. 15 While 3α NBD CA was efficiently taken up, all of the isomers underwent active transport. The same group recently reported on some transport characteristics of a series of 3-and 7α/β CA dansyl analogues in hepatocytes. 36 In this series the 7α-and β compounds appeared to be taken up to similar extents, and, although there was a marked difference in extent of uptake of the 3-isomers, there was still significant active uptake of the 3β-analogue.
Analogues of chenodeoxycholic acid (CDCA), CA, UDCA, DCA and lithocholic acid incorporating a 24-(NNBD)lysine were reported to be transported via OATP1B1 and 11 OATP1B3-expressing HepG2 cells. The CDCA analogue was most efficiently transported by both OATP subtypes with K m values one order of magnitude lower than observed in the present study for the 3α NBD compounds. 16 Fluorescent-lysyl analogues should properly be considered as reporters for the corresponding bile acid glycine conjugates since the terminal acid group is similarly placed with respect to the steroidal scaffold. In these compounds the pentyl-N(NBD reporter group replaces one of the hydrogen atoms on the glycyl methylene carbon. This arrangement, which substantially increases mass and steric bulk, produces high affinity substrates for OATPs (and ASBTs) but this kind of reporter is not suitable for investigating mechanistic questions related to unconjugated bile acids. It is important to note in this context that free DCA and UDCA possess chemical properties such as size, polarity and pK a that are distinct from their glycine and tauro conjugates and they cause different biological effects. mainly mediating the uptake of fluorescent bile acids, further uptake studies would need to be carried out in relevant heterologous expression systems. 3α-NBD DCA warrants further study as a tool for functional activity studies associated with organic anion transporter proteins. The specificity of the interactions suggests that the -compounds are able to mimic the natural 12 bile acid parents. The 3α-UDCA/DCA pair will be employed to investigate mechanistic aspects of the functional antagonism exhibited by these compounds in intestinal biology. 13 
Experimental
General synthetic methods
All chemicals were purchased from Sigma-Aldrich (Dublin, Ireland), except where stated. All the reactions were monitored using TLC. Uncorrected melting points were measured on a Stuart Apparatus. Infra-red (IR) spectra were performed on a Perkin Elmer FT-IR Paragon 1000 spectrometer. 1 H and 13 C nuclear magnetic resonance (NMR) spectra were recorded at 27°C on a Brucker DPX 400 spectrometer (400.13MHz, 1 H; 100.61MHz, was used. Mass measurement accuracies of < 5 ppm were obtained. Compound purity/homogeneity was confirmed using a combination of NMR, TLC and HPLC.
24-Methyl 3α-(methylsulfonyl)oxy, 7β-formyloxy-5β-cholanoate (10)
A solution of triethylamine (0.1 ml) and methanesulfonyl chloride (0.08 ml) in anhydrous DCM (5 ml) was added dropwise to a stirred solution of 8 (0.286 g) in anhydrous DCM (20 ml) at 0°C and the mixture allowed to warm to rt. After 20 min, when TLC analysis showed the reaction was complete, the mixture was poured into water (100 ml) and extracted with DCM (3 × 50 ml). The organic phase was dried over MgSO 4 then removed under reduced pressure to give the product as colourless semi-solid (0.330 g, 98% 
24-Methyl 3β-azido, 7β-hydroxy-5β-cholanoate (12)
To a stirred solution of 24-methyl 3β-azido, 7β-formyloxy-5β-cholanoate (0.308 g) in anhydrous MeOH (30 ml) was added acetyl chloride (0.06 ml in 5 ml anhydrous MeOH) dropwise at 0°C and allowed to warm to rt. The reaction was monitored by TLC until there was no starting material present. Then, the mixture was partitioned between saturated aq. NaHCO 3 and ethyl acetate. The organic phase was washed with water (2 × 100 ml) and brine (1 × 100 ml), dried over Na 2 SO 4 , filtered and the solvent removed under reduced 15 pressure to give the product as light yellow semi-solid (0.273 g, 97% 
24-Methyl 3β-(N-BOC), 7β-hydroxy-5β-cholanoate
To a pre-reduced suspension of 10 % Pd/C (~50 mg) in ethyl acetate (10 ml) was added a solution of 12 (0.273 g) and di-tert-butyl dicarbonate (0.166 g) in ethyl acetate (5 ml) under H 2 at rt and stirred overnight. Then the Pd/C was filtered out on a celite pad and the solvent was removed under reduced pressure. The crude product was cleaned on a flash column using 25% ethyl acetate in hexane as mobile phase to afford title compound as a white foam (0.276 g, 86% 
24-Methyl 3β-bromo, 7β-formyloxy-5β-cholanoate (14)
Triphenylphosphine (2.097 g) was added to a solution of 8 (1.738 g) in anhydrous THF (80 ml) and N-bromosuccinimide (1.423 g) was added in 3 parts over 1 h at -18°C then 17 allowed to warm to rt and stirred overnight. The reaction mixture was poured into 1 M HCl solution (100 ml) and extracted with ethyl acetate (3 × 75 ml). The organic layer was washed with brine (1 × 100 ml) and after drying over MgSO 4 the solvent was removed under reduced pressure. The crude product was flash columned (hexane/ethyl acetate 5:1)
to afford the product as white foam (1.694 g, 85% (M-Na) + = 519.2070.
24-Methyl 3α-azido, 7β-formyloxy-5β-cholanoate
To a solution of 14 (1.693 g) in DMPU (50 ml) was added sodium azide (2.21 g) at rt and stirred overnight. Then the reaction mixture was poured into water (100 ml) and extracted with ethyl acetate (3 × 75 ml). The organic phase was washed with brine (1 × 100 ml), dried over Na 2 SO 4 , filtered and the solvent was evaporated in vacuum. The crude product was cleaned on a flash column using hexane/ethyl acetate 5:1 as mobile phase to obtain the product as colourless oil (1.464 g, 94% 
24-Methyl 3α-(N-BOC), 7β-hydroxy-5β-cholanoate
Pd/C (~100 mg) in ethyl acetate (30 ml) was pre-reduced under H 2 atmosphere over 30 min then a solution of 16 (1.182 g) and di-tert-butyl dicarbonate (0.717 g) in ethyl acetate (20 ml) was added via syringe and the mixture stirred at rt overnight. The reaction mixture was filtered through a celite pad and washed with ethyl acetate (3 × 10 ml). The solvent was removed under reduced pressure and the crude product was flash columned using 30% ethyl acetate in hexanes as mobile phase to yield the product as white foam (1.300 g, 94% TFA/DCM (60 ml) and stirred at rt overnight (followed by TLC analysis using hexane/ethyl acetate 1:1 as mobile phase) then, the solvent was removed under vacuum.
The residue was further dried by successive evaporation of toluene (3 × 100 ml). The yield foam was dissolved in MeOH (50 ml) then NaHCO 3 (2.102 g) and NBD chloride (0.549 g)
were added to the solution. The reaction mixture was stirred vigorously for 2 weeks at reflux; reaction completion was checked by TLC using hexane:ethyl acetate (50:50) as mobile phase. It was poured into brine (150 ml) and extracted with ethyl acetate (3 × 100 ml). The organic phase was dried over Na 2 SO 4 , filtered and the solvent was removed in vacuum to afford the crude product as black semi-solid. This was purified with flash column using 40-70% ethyl acetate in hexanes as mobile phase to obtain the product as orange foam (0.622 g, 44% 
3α-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino, 7β-hydroxy-5β-cholanoate (3)
NaOH (2 M) was added to a stirred methanolic solution of 24-methyl 3α-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino, 7β-hydroxy-5β-cholanoate (0.589 g) and the mixture warmed to 40°C. The reaction mixture was left at this temperature overnight then poured into 2 M HCl (100 ml) and extracted with ethyl acetate (3 × 75 ml). 
24-Methyl 3α-(methylsulfonyl)oxy, 12α-formyloxy-5β-cholanoate (11)
The solution of triethylamine (0.1 ml) and methanesulfonyl chloride (0.15 ml) in anhydrous DCM (5 ml) was added drop-wise to a stirred solution of 9 (0.279 g) in anhydrous DCM (20 ml) at 0°C and allowed to warm to rt. After 20 min when TLC analysis showed the reaction was complete the mixture was poured into H 2 O (50 ml) and extracted with DCM (3 × 50 ml).
The organic phase was dried over MgSO 4 then removed under reduced pressure to give the product as colourless oil (0.322 g, 98% 
24-Methyl 3β-azido, 12α-formyloxy-5β-cholanoate
Sodium azide (0.408 g) was added to a stirred solution of 11 (0.322 g) in DMPU (20 ml) at 50°C and the reaction was monitored by TLC (hexane:ethyl acetate 5:1). After 6 d the mixture was partitioned between water and ethyl acetate. The organic phase was retrieved 21 and dried over Na 2 SO 4 . The crude product was cleaned by column chromatography using 20% ethyl acetate in hexane as mobile phase to yield colourless oil as product (0.253 g, 87% 
24-Methyl 3β-azido, 12α-hydroxy-5β-cholanoate (13)
To a stirred solution of 24-methyl 3β-azido, 12α-formyloxy-5β-cholanoate (0.322 g) in anhydrous MeOH (30 ml) was added acetyl chloride (0.07 ml in 5 ml anhydrous MeOH)
dropwise at 0°C and allowed to warm to rt. The reaction was monitored by TLC until there was no starting material present. Then the mixture was partitioned between saturated NaHCO 3 and ethyl acetate. The organic phase was washed with water (2 × 100 ml) and brine (100 ml), dried over Na 2 SO 4 , filtered and the solvent removed under reduced pressure to give the product as yellow semi-solid (0.294 g, 97% (M-Na) + = 454.3052.
24-Methyl 3β-(N-BOC), 12α-hydroxy-5β-cholanoate
To a pre-reduced suspension of 10% Pd/C (~50 mg) in ethyl acetate (10 ml) was added a solution of 13 (0.245 g) and di-tert-butyl dicarbonate (0.149 g) in ethyl acetate (5 ml 
3β-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino, 12α-hydroxy-5β-cholanoate (6)
The hydrolysis of 24-methyl 3β-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino, 12α-hydroxy-5β-cholanoate (0.205 g) was carried out in MeOH (20 ml) with 2 M NaOH at pH~14 at 40°C for 4 h. The mixture was poured into 2 M HCl (50 ml) and extracted with ethyl acetate (3 × 50 ml). The crude product was purified by column chromatography using 
24-Methyl 3β-bromo, 12α-formyloxy-5β-cholanoate (15)
Triphenylphosphine (2.135 g) was added to a solution of 9 (1.769 g) in anhydrous THF (80 ml) and N-bromosuccinimide (1.449 g) was added in 3 parts over 1 h at -18°C then allowed to warm to rt and stirred for 1.5 h. The reaction mixture was poured into 1 M HCl solution (100 ml) and extracted with ethyl acetate (3 × 75 ml). The organic layer was washed with brine (2 × 100 ml) and after drying over MgSO 4 the solvent was removed 24 under reduced pressure. The crude product was flash columned (hexane:ethyl acetate 5:1)
to afford the product as pale white solid (1.919 g, 95% 
24-Methyl 3α-azido, 12α-formyloxy-5β-cholanoate
To a solution of 15 (1.852 g) in DMPU (50 ml) was added sodium azide (2.420 g) at rt and stirred overnight. Then the reaction mixture was poured into water (100 ml) and extracted with ethyl acetate (3 × 50 ml). The organic phase was washed with brine (100 ml), dried over Na 2 SO 4 , filtered and the solvent was evaporated in vacuum. The crude product was cleaned on a flash column using hexane:ethyl acetate 5:1 as mobile phase to obtain the product as colourless semi-solid (1.652 g, 97%). 
24-Methyl 3α-azido, 12α-hydroxy-5β-cholanoate (17)
Acetyl chloride (0.51 ml) was added drop-wise to a stirred solution of 24-methyl 3α-azido, 12α-formyloxy-5β-cholanoate (1.645 g) in anhydrous MeOH (60 ml) at 0°C and allowed to warm to rt. After overnight stirring, the reaction mixture was poured into saturated NaHCO 3 (100 ml) and extracted with ethyl acetate (3 × 100 ml). The organic layer was 25 dried over Na 2 SO 4 , filtered and the solvent was removed under reduced pressure. The product was recrystallised from diethyl ether to obtain light-yellow crystals (1.457 g, 94 % 
24-Methyl 3α-(N-BOC), 12α-hydroxy-5β-cholanoate
A suspension of 10% Pd/C (~100 mg) in ethyl acetate (30 ml) was pre-reduced under hydrogen atmosphere over 30 min then the solution of 17 (1.424 g) and di-tert-butyl dicarbonate (0.864 g) in ethyl acetate (20 ml) was added via syringe and stirred at rt overnight. The reaction mixture was filtered through a celite pad and washed with ethyl acetate (3 × 10 ml). The solvent was removed under reduced pressure and the crude product was flash columned using 30% ethyl acetate in hexanes as mobile phase to yield the product as white foam (1.549 g, 93% (M-Na) + = 528.3666. 3α-(7-nitro-2,1,3-benzoxadiazol-4-yl) amino, 12α-hydroxy-5β-cholanoate 24-Methyl 3α-(N-BOC), 12α-hydroxy-5β-cholanoate (1.524 g) was dissolved in 10% TFA/DCM (60 ml) and stirred at rt overnight (followed by TLC analysis using 26 hexane:ethyl acetate 3:1 as mobile phase) then the solvent was removed in vacuum. The residue was dried under reduced pressure using toluene (3 × 100 ml). The yield foam was dissolved in MeOH (60 ml) then NaHCO 3 (2.533 g) and NBD chloride (0.862 g) were added to the solution. The reaction mixture was stirred vigorously for 10 d at reflux; reaction completion was checked by TLC using hexane:ethyl acetate (50:50) as mobile phase. It was poured into brine (100 ml) and extracted with ethyl acetate (3 × 100 ml). The organic phase was dried over Na 2 SO 4 , filtered and the solvent was removed in vacuum to afford the crude product as black semi-solid. This was purified with flash column using 
24-Methyl
3α-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino, 12α-hydroxy-5β-cholanoate (5)
Methyl 3α-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino, 12α-hydroxy-5β-cholanoate (1.621 g) was dissolved in a mixture of methanol and aq. NaOH (2 M) and the mixture warmed to 40°C. The reaction mixture was left at this temperature overnight then poured into 2 M HCl (100 ml) and extracted with ethyl acetate (3 × 100 ml). The organic layer was dried over Na 2 SO 4 , filtered and the solvent was removed under reduced pressure. The crude product was flash columned using first 20% hexane then 2% acetic acid in ethyl acetate as mobile phase to yield orange solid as product (0.997 g, 63% 
Stability and physiochemical characterisation
For the HPLC measurements, a WATERS Alliance system was used with 2475 Multi  (3) (4) (5) (6) was studied at different time points, concentrations and temperatures. Solutions of bile acid compounds were prepared using KRB containing 0.1% DMSO at all times.
Uptake studies
Time-dependence of bile acid uptake was studied by incubating cell monolayers (at 10 μM) for up to 90 min at either 37°C or 4°C. After 5, 10, 15, 30, 45, 60 and 90 min, monolayers were washed twice with ice-cold KRB, solubilised in 1% (w/v) Triton X-100 solution and bile acid activity was measured in the cell lysate (see below). Concentration-dependence of bile 29 acid uptake was studied at a compound concentration range of 1 to 100 µM for 20 min at 37°C and 4°C. Active uptake of bile acid compounds was calculated as the difference between the fluorescence, after exposure to compounds 3-6 at 37°C and 4°C.
The fluorescence activity of the bile acids compounds was analysed in 24-well plates using an automated plate reader (FLUOstar Optima, BMG Labtech, Offenburg, Germany) at excitation and emission wavelengths of 485 and 520 nm, respectively. The samples were diluted with KRB, where appropriate. For standardization, the total protein amount of cell layers was determined by bicinchoninic acid (BCA) assay according to the manufacturer's instructions (Pierce, Thermo Scientific, Rockford, USA).
Uptake kinetics
The saturable uptake of the bile acid compounds was analysed by assuming MichaelisMenten type carrier-mediated transport represented by the equation:
where (S) was [bile acid compound].
Half-saturation constant (K m ) and maximum uptake rates (V max ) of the bile acid compounds was calculated by this equation to the experimental profile of the uptake rate (ν) versus the substrate concentration (S) using a non-linear least squares regression analysis program, WinNonlin (Pharsight, Mountain View, CA, USA).
Molecular modelling
The strucutres of DCA and its 3-α and -β NBD analogues were generated by in silico modification in MOE (Chemical Computing Group, Montreal, Canada) of cholic acid extracted from pdb code 2QO4 37 The bile acid models were energy minimised using Merck Molecular Force Field 94x (MMFF94x ) interfaced to MOE with gradient 0.5. Then structures were further manipulated in MOE and the picture in Figure 6 generated using the programme PyMOL. 30 
Statistical analysis
All uptake studies were performed in triplicate. Results were expressed as mean ± S.D., were compared using one-way analysis of variance (ANOVA) followed by Student-NewmanKeuls post hoc test. P < 0.05 was considered as significant. 
